The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.

Formulations of oxabicycloheptanes and oxabicycloheptenes

Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.

Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

The present disclosure provides methods for purifying a solution comprising cantharidin and cantharidin-associated impurities. A method to purify the solution can comprise recrystallization or sublimation, for example. The purified cantharidin can be analyzed using a detection method comprising a stationary phase and one or more mobile phases.

Quantification and preparation of pharmaceutical grade cantharidin

This chapter deals with small molecule modulators of the refolding machinery centered around heat shock proteins (Hsps). They are designed to restore its impaired refolding capacity to rescue dysfunctional proteins, and to fight its pathological alterations in proteinopathies in general and in tauopathies in particular. Three key Hsp families are targeted in particular (either as such, or as members of chaperone–co-chaperone complexes) for therapeutic intervention against neurodegenerative diseases (NDDs): the small Hsp family, Hsp70, and Hsp90. Known modulators of each target (either by direct interaction with the Hsps, or by inhibition of chaperone–co-chaperone interactions, or by indirect control of their activation/expression/post-translational modification) are described in terms of their biological profile, and of their development potential as disease-modifying drugs against NDDs.

Targeting the Protein Quality Control (PQC) Machinery

The present invention provides a process for producing the compound having the structure: (formula) comprising, (a) reacting a compound having the structure : (formula) with a compound having the structure: (formula) in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.

Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid

IPI-504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer IPI-504 is an aqueous soluble (>200 mg/ml) hydroquinone hydrochloride salt of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), a quinone derivative also undergoing clinical evaluation, albeit with suboptimal formulations that address its inferior aqueous solubility (∼50 µg/ml) IPI-504 interconverts with 17-AAG in vivo through oxidation-reduction reactions that result in a dynamic redox equilibrium The development challenges associated with redox active molecules are significant due to the pH, oxygen, and temperature sensitivities associated with such chemotypes The API and sterile drug product manufacturing processes thus warrant the monitoring and control of these key variables Furthermore, the pharmaceutical development challenges associated with cancer agents that are often fast-tracked due to unmet medical needs mandate a rapid development cycle with associated regulatory hurdles Drug Dev Res 71: 429–438, 2010 © 2010 Wiley-Liss, Inc

Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

Dumitru Ionescu

Author Tools

Chat about Author

Papers

Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid

Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer